Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 17, 2018 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer

NOVATO, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
August 30, 2018 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at Upcoming Investor Conferences

NOVATO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
August 29, 2018 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces FDA Accepts Proposal to Submit an NDA for UX007 for the Treatment of Long-Chain Fatty Acid Oxidation Disorders

NOVATO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
August 27, 2018 16:01 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII

NOVATO, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
August 02, 2018 16:05 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update

NOVATO, Calif, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
July 27, 2018 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results and Corporate Update

NOVATO, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
July 26, 2018 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces First Patient Dosed in Phase 1/2 study of DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa); FDA Grants Fast Track Designation to Gene Therapy Program

NOVATO, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
June 29, 2018 09:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII

NOVATO, Calif., June 29, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific...
June 04, 2018 16:05 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at Upcoming Investor Conferences

NOVATO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
May 23, 2018 17:01 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

NOVATO, Calif., TOKYO, JAPAN, and LONDON, May 23, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Kyowa Hakko Kirin Co. Ltd, and Kyowa Kirin International PLC today announced...